Abstract
Current guidelines for prevention and monitoring cardiac dysfunction in patients with cancer state that there is insufficient evidence to support surveillance strategies for TKIs alone. Furthermore, risk stratification for baseline and frequency of monitoring remains unclear for various products. This study evaluates the current practice of screening and monitoring for cardiotoxicity in patients treated for non-small cell lung cancer (NSCLC) with TKIs and the adherence rate to the standards of care.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
